Presence and toxicity of drugs used to treat SARS-CoV-2 in Llobregat River, Catalonia, Spain

Dominguez-García, Pol; Rodríguez, Reinerio Rolando; Barata, Carlos; Gómez-Canela, Cristian

doi:10.1007/s11356-023-25512-9

Cited by 13 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several drugs are clinically employed to combat COVID-19, including antiviral agents such as remdesivir [ 133 ], lopinavir/ritonavir, and interferons [ 134 , 135 ]; antibiotics such as macrolides; antimalarial/antirheumatic drugs such as hydroxychloroquine; immunomodulatory drugs like corticosteroids and tocilizumab; and anti-fever medications such as acetaminophen [ 136 ]. However, many of these drugs have been associated with hepatotoxicity [ 137 , 138 ].…”

Section: The Hepatic Implications Of Covid-19mentioning

confidence: 99%

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

Buchynskyi

Kamyshna

Oksenych

et al. 2023

Viruses

View full text Add to dashboard Cite

The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a pervasive public health concern intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and MAFLD is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among MAFLD patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of MAFLD on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations.

show abstract

Section: The Hepatic Implications Of Covid-19mentioning

confidence: 99%

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

Buchynskyi

Kamyshna

Oksenych

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Several drugs are clinically employed to combat COVID-19, including antiviral agents such as remdesivir [127], lopinavir/ritonavir and interferons [128,129], antibiotics such as macrolides, antimalarial/antirheumatic drugs such as hydroxychloroquine, immunomodulatory drugs like corticosteroids and tocilizumab, and anti-fever medications such as acetaminophen [130]. However, many of these drugs have been associated with hepatotoxicity [131,132].…”

Section: The Hepatic Implications Of Covid-19mentioning

confidence: 99%

The Intersection of COVID-19 and MAFLD: An Overview of the Current Evidence

Buchynskyi¹,

Kamyshna²,

Oksenych³

et al. 2023

Preprint

View full text Add to dashboard Cite

The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. By our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD) is a pervasive public health concern, intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and metabolic dysfunction-associated fatty liver disease (MAFLD) is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among metabolic dysfunction-associated fatty liver disease (MAFLD) patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of metabolic dysfunction-associated fatty liver disease (MAFLD) on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations.

show abstract

“…Selection method of assessment factor; Table S5. Comparison of pharmaceutical concentrations between the North Canal Basin and other study areas [ 16 , 42 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 ]; Table S6. PNEC values of pharmaceuticals and calculated method; Table S7.…”

mentioning

confidence: 99%

Occurrence, Source Apportionment, and Ecological Risk of Typical Pharmaceuticals in Surface Waters of Beijing, China

Huangfu,

Li,

Yang

et al. 2024

Toxics

View full text Add to dashboard Cite

Various studies have shown that the heavy use of pharmaceuticals poses serious ecological risks, especially in metropolitan areas with intensive human activities. In this study, the spatial distribution, sources, and ecological risks of 29 pharmaceuticals in 82 surface waters collected from the North Canal Basin in Beijing were studied. The results showed that the pharmaceutical concentrations ranged from not detected to 193 ng/L, with ampicillin being undetected while ofloxacin had a 100% detection frequency, which indicates the widespread occurrence of pharmaceutical pollution in the North Canal Basin. In comparison with other freshwater study areas, concentrations of pharmaceuticals in the North Canal Basin were generally at moderate levels. It was found that pharmaceutical concentrations were always higher in rivers that directly received wastewater effluents. Source analysis was conducted using the positive matrix factorization model. Combining the spatial pollution patterns of pharmaceuticals, it has been found that wastewater effluents contributed the most to the loads of pharmaceuticals in the studied basin, while in suburban areas, a possible contribution of untreated wastewater was demonstrated. Risk assessment indicated that approximately 55% of the pharmaceuticals posed low-to-high ecological risks, and combining the results of risk analyses, it is advised that controlling WWTP effluent is probably the most cost-effective measure in treating pharmaceutical pollution.

show abstract

Presence and toxicity of drugs used to treat SARS-CoV-2 in Llobregat River, Catalonia, Spain

Cited by 13 publications

References 50 publications

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

The Intersection of COVID-19 and MAFLD: An Overview of the Current Evidence

Occurrence, Source Apportionment, and Ecological Risk of Typical Pharmaceuticals in Surface Waters of Beijing, China

Contact Info

Product

Resources

About